| Literature DB >> 33526951 |
Dhaybia Douche1, Yusuf Sert2, Silvia A Brandán3, Ameed Ahmed Kawther4, Bayram Bilmez4, Necmi Dege4, Ahmed El Louzi1, Khalid Bougrin1,5, Khalid Karrouchi6, Banacer Himmi7,6.
Abstract
A potential new drug to treat SARS-CoV-2 infections and chloroquine analogue, 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol (DD1) has been here synthesized and characterized by FT-IR, 1H-NMR, 13C-NMR, ultraviolet-visible, ESI-MS and single-crystal X-ray diffraction. DD1 was optimized in gas phase, aqueous and DMSO solutions using hybrid B3LYP/6-311++G(d,p) method. Comparisons between experimental and theoretical infrared spectra, 1H and 13C NMR chemical shifts and electronic spectrum in DMSO solution evidence good concordances. Higher solvation energy was observed in aqueous solution than in DMSO, showing in aqueous solution a higher value than antiviral brincidofovir and chloroquine. on Bond orders, atomic charges and topological studies suggest that imidazole ring play a very important role in the properties of DD1. NBO and AIM analyses support the intra-molecular O15-H16•••N17 bonds of DD1 in the three media. Low gap value supports the higher reactivity of DD1 than chloroquine justified by the higher electrophilicity and low nucleophilicity. Complete vibrational assignments of DD1 in gas phase and aqueous solution are reported together with the scaled force constants. In addition, better intermolecular interactions were observed by Hirshfeld surface analysis. Finally, the molecular docking mechanism between DD1 ligand and COVID-19/6WCF and COVID-19/6Y84 receptors were studied to explore the binding modes of these compounds at the active sites. Molecular docking results have shown that the DD1 molecule can be considered as a potential agent against COVID-19/6Y84-6WCF receptors.Entities:
Keywords: Coronavirus; DFT; Hirshfeld surface analysis; Molecular docking; Quinoline; X-ray
Year: 2021 PMID: 33526951 PMCID: PMC7839438 DOI: 10.1016/j.molstruc.2021.130005
Source DB: PubMed Journal: J Mol Struct ISSN: 0022-2860 Impact factor: 3.196
Fig. 1Molecular structures of Chloroquine, Hydroxychloroquine, and DD1.
Scheme 1Synthetic route of DD1.
Crystal data, data collection and structure refinement details for DD1.
| Crystal data | |
|---|---|
| Chemical formula | C13H11N3O |
| 225.25 | |
| Crystal system, space group | Monoclinic, |
| Temperature (K) | 296 |
| 10.2882 (5), 9.7521 (6), 11.0496 (5) | |
| β (°) | 104.134 (4) |
| 1075.06 (10) | |
| 4 | |
| Radiation type | Mo |
| µ (mm−1) | 0.09 |
| Crystal size (mm) | 0.78 × 0.60 × 0.49 |
| Data collection | |
| Diffractometer | STOE |
| Absorption correction | Integration ( |
| 0.958, 0.979 | |
| No. of measured, independent and observed [ | 11136, 3202, 2026 |
| 0.033 | |
| (sin θ/λ)max (Å−1) | 0.710 |
| Refinement | |
| 0.042, 0.111, 1.00 | |
| No. of reflections | 3202 |
| No. of parameters | 155 |
| H-atom treatment | H-atom parameters constrained |
| Δρmax, Δρmin (e Å−3) | 0.17, −0.14 |
Fig. 2The molecular structure (ORTEP) of the compounds DD1.
Fig. 3A view of the crystal packing of compound DD1 with O—H•••N and C—H•••N hydrogen bonds.
Hydrogen-bond geometry (Å, °) for DD1.
| O1—H1•••N3i | 0. 82 | 1.92 | 2.701 (15) | 157.9 |
Symmetry code: (i) x+1, y, z
Fig. 4Comparisons between the most stable theoretical and experimental DD1 structures, definitions of rings and atoms labeling.
Calculated total energies (E), dipole moments (µ) and volumes (V) of 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol in gas phase and aqueous and DMSO solutions by using the B3LYP/6-311++g(d,p) Method.
| B3LYP/6-311++G(d,p) Method | |||||
|---|---|---|---|---|---|
| Medium | E (Hartrees) | EZPVE (Hartrees) | µ (D) | V (Å3) | ΔV (Å3) |
| Gas phase | -741.6819 | -741.4622 | 4.03 | 238.8 | -1.2 |
| Water | -741.5023 | -741.2810 | 5.93 | 237.6 | |
| DMSO | -741.5074 | -741.2859 | 5.83 | 237.2 | -1.6 |
Corrected (ΔGcZPVE) and uncorrected (ΔGc) solvation energies by the total non-electrostatic terms and by zero point vibrational energy (ZPVE) of 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol in aqueous and DMSO solutions by using the B3LYP/6-311++G(d,p) method.
| B3LYP/6-311++G(d,p) Method | ||||
|---|---|---|---|---|
| Solvation energy (kJ/mol) | ||||
| Species | ΔGun# | ΔGne | ΔGc | ΔGcZPVE |
| Water | -471.09 | 15.13 | -486.22 | -490.41 |
| DMSO | -457.71 | -7.73 | -449.98 | -454.70 |
ΔGun#= uncorrected solvation energy, ΔGne= total non-electrostatic terms, ΔGc= corrected solvation energies.
This work
Comparisons of calculated geometrical parameters of 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol in gas phase and aqueous and DMSO solutions with the corresponding experimental ones.
| B3LYP/6-311++g(d,p) Method | Experimental | |||
|---|---|---|---|---|
| Parameters | Gas phase | Water | DMSO | |
| Bond lengths (Å) | ||||
| C8-C18 | 1.510 | 1.510 | 1.511 | 1.517 |
| C8-C12 | 1.380 | 1.383 | 1.383 | 1.369 |
| C12-C11 | 1.411 | 1.413 | 1.413 | 1.400 |
| C11-C9 | 1.375 | 1.377 | 1.378 | 1.371 |
| C9-O15 | 1.346 | 1.363 | 1.351 | 1.341 |
| C9-C4 | 1.430 | 1.429 | 1.431 | 1.426 |
| O15-H16 | 0.975 | 0.981 | 0.984 | 0.820 |
| C4-C3 | 1.424 | 1.426 | 1.425 | 1.423 |
| C3-C8 | 1.429 | 1.431 | 1.432 | 1.419 |
| C3-C2 | 1.418 | 1.420 | 1.420 | 1.416 |
| C2-C1 | 1.375 | 1.377 | 1.378 | 1.352 |
| C1-C5 | 1.411 | 1.412 | 1.413 | 1.394 |
| C5-N17 | 1.317 | 1.322 | 1.321 | 1.311 |
| N17-C4 | 1.356 | 1.362 | 1.360 | 1.364 |
| C18-N21 | 1.470 | 1.475 | 1.475 | 1.467 |
| N21-C22 | 1.381 | 1.380 | 1.380 | 1.365 |
| C22-C24 | 1.371 | 1.371 | 1.373 | 1.341 |
| C24-N28 | 1.374 | 1.382 | 1.379 | 1.365 |
| N28-C23 | 1.315 | 1.324 | 1.322 | 1.312 |
| C23-N21 | 1.367 | 1.361 | 1.362 | 1.340 |
| Bond angles | ||||
| C18-C8-C3 | 121.6 | 121.7 | 121.7 | 121.7 |
| C18-C8-C12 | 119.9 | 119.6 | 119.7 | 119.7 |
| C8-C12-C11 | 122.9 | 122.6 | 122.9 | 122.7 |
| C12-C11-C9 | 119.5 | 119.5 | 119.5 | 120.4 |
| C11-C9-C4 | 119.6 | 120.1 | 119.6 | 118.9 |
| C9-C4-C3 | 120.2 | 119.8 | 120.3 | 120.1 |
| C4-C3-C8 | 119.1 | 119.2 | 119.0 | 119.3 |
| C3-C8-C12 | 118.3 | 118.5 | 118.4 | 118.6 |
| C4-C3-C2 | 115.8 | 116.0 | 115.8 | 115.9 |
| C3-C2-C1 | 119.8 | 119.7 | 119.8 | 120.1 |
| C2-C1-C5 | 119.3 | 119.3 | 119.3 | 119.4 |
| C1-C5-N17 | 122.8 | 123.2 | 122.8 | 124.0 |
| C5-N17-C4 | 118.2 | 117.7 | 118.1 | 117.4 |
| N17-C4-C3 | 123.7 | 123.8 | 123.9 | 123.1 |
| C9-O15-H16 | 106.0 | 105.4 | 104.9 | 109.5 |
| C8-C18-N21 | 114.1 | 113.6 | 113.7 | 113.4 |
| C18-N21-C23 | 127.7 | 127.3 | 127.0 | 125.9 |
| C18-N21-C22 | 125.7 | 125.9 | 126.0 | 127.7 |
| N21-C23-N28 | 112.0 | 112.3 | 112.1 | 112.1 |
| C23-N28-C24 | 105.3 | 104.6 | 105.0 | 104.8 |
| N28-C24-C22 | 110.3 | 110.5 | 110.3 | 110.4 |
| C24-C22-N21 | 105.7 | 105.7 | 105.7 | 106.3 |
| C22-N21-C23 | 106.3 | 106.6 | 106.7 | 106.4 |
| Dihedral angles (°) | ||||
| C18-C8-C3-C2 | 2.006 | 0.245 | 0.125 | 1.230 |
| C18-C8-C12-H14 | -1.666 | -0.381 | -0.337 | -3.491 |
| H16-O15-C9-C4 | 0.155 | 0.289 | -0.155 | -26.221 |
| H16-O15-C9-C11 | -179.856 | -179.799 | 179.745 | 154.383 |
| O15-C9-C11-H13 | 0.062 | -0.174 | -0.139 | 2.0387 |
| C5-N17-C4-C9 | 179.990 | 179.800 | 179.681 | 177.617 |
This work, Bold letter, RMSD values
Fig. 5Experimental Infrared spectra of 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol (DD1) in the solid phase compared with the predicted in gas phase and aqueous and DMSO solution by using the hybrid B3LYP/6-311++G** method.
Fig. 6Predicted Raman spectrum of 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol (DD1) in gas phase and aqueous and DMSO solution by using the hybrid B3LYP/6-311++G** method.
Observed and calculated wavenumbers (cm−1) and assignments for 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol (DD1) in gas phase and aqueous solution by using the B3LYP/6-311++G(d,p) Method.
| Exp | DD1 | ||||
|---|---|---|---|---|---|
| GAS | PCM | ||||
| IR | Int | SQM | Assignments | SQM | Assignments |
| 3490vw | 113.8 | 3480 | νO15-H16 | 3409 | νO15-H16 |
| 3168w | 2.5 | 3125 | νC22-H25 | 3162 | νC22-H25 |
| 3120sh | 1.1 | 3115 | νC23-H26 | 3157 | νC23-H26 |
| 3100sh | 4.6 | 3101 | νC24-H27 | 3133 | νC24-H27 |
| 3092w | 7.3 | 3068 | νC2-H7 | 3100 | νC1-H6 |
| 3080sh | 4.6 | 3066 | νC11-H13 | 3091 | νC11-H13 |
| 3044vw | 5.0 | 3054 | νC1-H6 | 3087 | νC2-H7 |
| 10.7 | 3032 | νC12-H14 | 3070 | νC12-H14 | |
| 2989w | 16.7 | 3024 | νC5-H10 | 3066 | νC5-H10 |
| 2969w | 10.0 | 2943 | νaCH2 | 3004 | νaCH2 |
| 2913w | 30.5 | 2911 | νsCH2 | 2962 | νsCH2 |
| 1687w | 14.4 | 1610 | νC9-C11 | 1624 | νC9-C11,νC8-C12 |
| 1616w | 6.1 | 1582 | νC1-C2,νC8-C12 | 1597 | νC1-C2 |
| 1568m | 37.9 | 1563 | νC5-N17 | 1578 | νC5-N17 |
| 1500s | 134.8 | 1488 | νC1-C5 | 1509 | νC23-N21 |
| 0.3 | 1481 | νC22-C24 | 1502 | νC22-C24 | |
| 1472s | 60.0 | 1474 | νC23-N28,βC23-H26 | 1500 | νC1-C5,βC1-H6 |
| 1448m | 104.9 | 1457 | νC4-C9 | 1465 | βC5-H10,νC4-C9 |
| 1436sh | 24.7 | 1435 | δCH2 | 1454 | δCH2 |
| 1409m | 14.5 | 1407 | βC5-H10 | 1421 | wagCH2,βC5-H10 |
| 15.0 | 1394 | βC2-H7,νC3-C8 | 1412 | wagCH2 | |
| 1388m | 24.4 | 1387 | wagCH2 | 1409 | βC2-H7 |
| 1368m | 49.6 | 1356 | νC3-C4,νC8-C12 | 1367 | νC3-C4 |
| 1345m | 26.8 | 1332 | νC3-C4 | 1343 | νC5-N17,νC3-C4 |
| 1333sh | 2.5 | 1325 | νC23-N28 | 1333 | νC23-N28 |
| 1297sh | 20.0 | 1296 | νC23-N21 | 1330 | νC23-N28,νC23-N21 |
| 1269s | 68.9 | 1266 | βR1(A2) | 1278 | βC24-H27 |
| 1269s | 80.2 | 1264 | βC24-H27 | 1265 | βR1(A2) |
| 1237vs | 10.7 | 1245 | βC12-H14 | 1259 | βC12-H14 |
| 1237vs | 121.6 | 1219 | νC4-N17,νC9-O15 | 1226 | βC23-H26,νC18-N21 |
| 1217sh | 61.9 | 1211 | νC18-N21 | 1214 | νC2-C3, νC3-C8,νC4-N17 |
| 1205sh | 34.2 | 1191 | ρCH2 | 1204 | ρCH2 |
| 1181m | 11.0 | 1180 | δO15-H16,νC2-C3 | 1172 | δO15-H16 |
| 1150m | 3.4 | 1143 | βC11-H13 | 1149 | βC1-H6 |
| 1142sh | 2.8 | 1137 | βC1-H6,νC11-C12,νC8-C18 | 1137 | νC11-C12,βC11-H13,νC9-O15 ,νC8-C18 |
| 1102sh | 22.9 | 1100 | νC24-N28 | 1101 | νC24-N28 |
| 1074s | 2.5 | 1068 | βR1(A1) | 1067 | βC22-H25 |
| 1054sh | 40.3 | 1058 | βC22-H25 | 1062 | βR1(A1) |
| 1030m | 1.5 | 1044 | νC1-C5,βR1(A1) | 1056 | νC1-C5 |
| 1010sh | 5.0 | 1017 | νC22-N21 | 1019 | βR1(A3),νC22-N21 |
| 18.3 | 1001 | νC1-C5 | 1005 | νC1-C5 | |
| 986sh | 0.4 | 989 | γC1-H6 | 999 | γC1-H6 |
| 951sh | 1.5 | 952 | γC5-H10,γC2-H7 | 967 | γC5-H10 |
| 927m | 0.8 | 945 | γC12-H14 | 953 | γC12-H14 |
| 911sh | 2.9 | 909 | βR2(A3) | 912 | βR2(A3) |
| 871sh | 8.6 | 882 | τwCH2 | 891 | τwCH2 |
| 859sh | 1.9 | 854 | γC24-H27 | 850 | γC11-H13 |
| 843sh | 21.6 | 841 | γC11-H13 | 842 | γC24-H27 |
| 823s | 4.6 | 827 | βR3(A1) | 827 | γC23-H26 |
| 823s | 25.5 | 814 | γC23-H26 | 826 | βR3(A1) |
| 791s | 26.6 | 805 | τR1(A1), γC2-H7 | 816 | γC2-H7 |
| 752sh | 20.9 | 779 | τR1(A2) | 778 | τR1(A2),τR1(A1) |
| 728vs | 3.3 | 765 | τR1(A1), τR1(A2) | 760 | τR1(A1), βR1(A2) |
| 728vs | 10.1 | 725 | τR1(A1), νC18-N21 | 732 | γC22-H25 |
| 696s | 34.4 | 715 | γC22-H25 | 728 | τR1(A1), νC18-N21 |
| 696s | 25.6 | 696 | βR2(A1) | 695 | βR2(A1) |
| 660s | 15.6 | 651 | τR1(A3) | 653 | τR1(A3) |
| 640m | 33.8 | 632 | τR1(A1) | 629 | τR1(A1), τR1(A2) |
| 620m | 65.1 | 603 | τR2(A3) | 602 | τR2(A3) |
| 6.5 | 593 | γC9-O15 | 595 | γC9-O15 | |
| 577w | 1.3 | 570 | βR2(A1), γC9-O15 | 567 | βR2(A1), γC9-O15 |
| 7.7 | 569 | τO15-C9 | 535 | βR3(A1) | |
| 545sh | 0.6 | 537 | βR2(A2) | 504 | βR2(A2) |
| 17.6 | 507 | βR2(A2) | 492 | τO15-C9 | |
| 493m | 0.6 | 492 | βR3(A2) | 490 | βR3(A2) |
| 465w | 0.2 | 459 | τR2(A2) | 463 | τR2(A2) |
| 453sh | 1.9 | 413 | τR3(A1) | 413 | τR3(A1) |
| 0.9 | 353 | τR2(A2), τR2(A1) | 360 | τR2(A2), τR2(A1) | |
| 1.5 | 312 | βN21-C18 | 330 | βN21-C18 | |
| 3.2 | 280 | γC9-O15 | 277 | βN21-C18,βR2(A2) | |
| 2.4 | 272 | βR3(A2), βC8-C18 | 269 | γC9-O15 | |
| 2.2 | 192 | βC8-C18 | 196 | βC8-C18 | |
| 2.3 | 177 | ButC3-C4,γN21-C18 | 177 | ButC3-C4,γN21-C18 | |
| 0.1 | 148 | τR3(A2) | 146 | τR3(A2) | |
| 0.6 | 132 | τR2(A1) | 133 | τR2(A1) | |
| 1.3 | 50 | γC8-C18,δC8C18N21 | 48 | γC8-C18,δC8C18N21 | |
| 0.3 | 36 | τC18-N21 | 41 | τC18-N21 | |
| 2.9 | 33 | τC18-C8 | 25 | τC18-C8 | |
Abbreviations: ν, stretching; β, deformation in the plane; γ, deformation out of plane; wag, wagging; τ, torsion; βR, deformation ring τR, torsion ring; ρ, rocking; τw, twisting; δ, deformation; a, antisymmetric; s, symmetric; (A1), Ring 1; (A2), Ring 2; (A3), Ring 3;
This work,
Intensities in KM/Mole;
From scaled quantum mechanics force field.
Scaled internal force constants of 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol (DD1) in gas phase and aqueous and DMSO solutions by using the B3LYP/6-311++G** method.
| Force constant | B3LYP/6-311++G** method | ||
|---|---|---|---|
| DD1 | |||
| GAS | Water | DMSO | |
| 6.77 | 6.49 | 6.32 | |
| 6.22 | 5.46 | 6.47 | |
| 5.09 | 5.22 | 5.20 | |
| 5.10 | 5.20 | 5.19 | |
| 5.30 | 5.43 | 5.39 | |
| 7.82 | 7.86 | 7.91 | |
| 7.66 | 7.59 | 7.71 | |
| 4.73 | 4.90 | 4.89 | |
| 0.78 | 0.79 | 0.79 | |
| 0.83 | 0.82 | 0.87 | |
Units are mdyn Å−1 for stretching and mdyn Å rad−2 for angle deformations
This work
Results of the binding affinity and RMSD values of different poses in COVID-19/6Y84 inhibitor of DD1.
| Modes | Affinity (kcal/mol) | rmsdl.b. | rmsdu.b. |
|---|---|---|---|
| 1 | -7.2 | 0.000 | 0.000 |
| 2 | -6.9 | 1.620 | 3.413 |
| 3 | -6.7 | 3.642 | 5.463 |
| 4 | -6.5 | 7.963 | 9.477 |
| 5 | -6.5 | 1.560 | 2.830 |
| 6 | -6.4 | 5.758 | 7.446 |
| 7 | -6.3 | 9.830 | 11.517 |
| 8 | -6.3 | 4.190 | 5.324 |
| 9 | -6.2 | 2.843 | 5.654 |
| 10 | -6.1 | 15.600 | 17.436 |
Inhibition Constant: 5.27669 μM
Number of Hydrogen bonding: 1 active bonding
Results of the binding affinity and RMSD values of different poses in COVID-19/6WCF inhibitor of DD1.
| Modes | Affinity (kcal/mol) | rmsdl.b. | rmsdu.b. |
|---|---|---|---|
| 1 | -6.2 | 0.000 | 0.000 |
| 2 | -6.1 | 14.750 | 15.700 |
| 3 | -6.0 | 14.379 | 15.520 |
| 4 | -5.9 | 22.551 | 24.206 |
| 5 | -5.8 | 14.275 | 15.767 |
| 6 | -5.8 | 24.802 | 25.867 |
| 7 | -5.8 | 22.076 | 23.739 |
| 8 | -5.7 | 7.108 | 8.948 |
| 9 | -5.7 | 13.539 | 14.413 |
| 10 | -5.6 | 19.175 | 20.321 |
Inhibition Constant: 28.5343 μM
Number of Hydrogen bonding: 4 non-active bonding
Fig. 7dnorm mapped on Hirshfeld surface for visualizing the intercontacts of DD1.
Fig. 8Finger plots of compound DD1.
Fig. 9The molecular docking results of the DD1 compound with 6Y84 protein, surfaces around ligand (a) and 2D forms (b).
Fig. 10The molecular docking positions of the DD1 compound within 6Y84 protein.
Fig. 11The molecular docking results of the DD1 compound with 6WCF protein, surfaces around ligand (a) and 2D forms (b).
Fig. 12The molecular docking positions of DD1 within 6WCF protein.